Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Crystallization (Commentary)

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search

Search term:

Results 1 - 10 of 20 > >>
EC Number Crystallization (Commentary) Reference
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23recombinant enzyme, hanging drop vapor diffusion method 643073
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23- 643075, 643076
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23sitting-drop vapour-diffusion method 671097
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23hanging drop vapour diffusion method 674815
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23hanging drop vapour diffusion method, using 20% PEG 3350, 0.15 M DL-malate pH 7.0 690292
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23a 1.9 A resolution crystal structure of a synthetic small-molecule inhibitor (4-chloro-N-(3-methoxypropyl)-N-[1-(2-phenylethyl)piperidin-3-yl]benzamide) of GlmU is presented. The determined crystal structure indicate that the inhibitor occupies an allosteric site adjacent to the GlcNAc-1-P substrate-binding region, thus, preventing structural rearrangements that are required for the enzymatic reaction 706622
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23homology modeling of structure based on Haemophilus influenzae enzyme, PDB entry 2V0K 719411
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23GlmUMtb in complex with substrates/products bound at the acetyltransferase active site, sitting drop vapor diffusion method, mixing of 400 nl of 15 mg/ml protein, 5 mM acetyl-CoA, 5 mM MgCl2, 5 mM UDP-GlcNAc with 400 nl of 18% PEG 3350, 0.1 M Tris-Cl, pH 8.5, and 2% tacsimate, 4-8 days, for enzyme complex with CoA and N-acetylglucosamine-1-phosphate, acetyl-Coa-containing crystals are soaked in 5 mM GlcN-1-P, 5 mM MgCl2, 5 mM UDP-GlcNAc, 5 mM acetyl-CoA, 18% PEG 3350, 0.1 M Tris-Cl, pH 8.5, and 2% tacsimate, or by co-crystallizing the enzyme with 5 mM GlcNAc-1-P, 5 mM MgCl2, 5 mM UDPGlcNAc, and 5 mM CoA under the conditions mentioned for obtaining GlmUMtb(AcCoA) crystals, X-ray diffraction structure determination and analysis at 1.98-2.33 A resolution 720042
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23generation of a three-dimensional model, using human GlcNAc1p nucleotidyltransferase complexed with UDP-GlcNAc, PDB code 1JV1 721526
Show all pathways known for 2.7.7.23Display the word mapDisplay the reaction diagram Show all sequences 2.7.7.23structure-based drug design studies. The molecular recognition of the enzyme with the substrates occurs mainly by hydrogen bonds between ligands and Arg116, Arg383, Gly381, and Lys408 amino acids, and few hydrophobic interactions with Tyr382 and Lys123 residues 722022
Results 1 - 10 of 20 > >>